TL;DR
It seems that the infected male mice with the recent SARS-CoV-2/2025 could suffer from milder clinical signs than the infected female mice because of the increased expression of immune-enhancing cytokines and anti-apoptotic genes.
The reduced pathogenicity of rSARS-CoV-2 Nsp1 mutants highlights the potential for targeting Nsp1 for rational design of viral inhibitors and development of live-attenuated vaccine strategies as effective prophylactic and therapeutic treatments to combat SARS-CoV-2 and possibly other CoV infections.
ABSTRACT In immunocompromised patients, persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection carries the risk of prolonged viral shedding and emergence of new variants. To reproduce the key features of persistent SARS-CoV-2 infection and evaluate its transmissibility, mouse-passaged SARS-Co...
Overall, SARS-CoV-2 coinfection was associated with a distinct pulmonary immune landscape compared to TB alone, including differences in macrophage and lymphocyte composition and spatial organization, suggesting that coinfection may modulate the local immune response to TB and highlighting the need for further investig...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), can infect a broad range of mammalian species, including companion animals. Early reports during 2020 established that cats and dogs can acquire SARS-CoV-2, particularly after close contact with inf...
The infant mouse model is used to define the role of the accessory protein ORF8 in SARS-CoV-2 spread and reveal how a SARS-CoV-2 accessory protein can exploit mucosal antiviral responses to increase host contagiousness.
ABSTRACT Yezo virus (YEZV) is an emerging tick-borne orthonairovirus that causes febrile illness and hepatic injury in humans. However, its pathogenesis and effective antiviral interventions remain poorly characterized. In this study, we generated a lethal, mouse-adapted YEZV strain through 30 serial passages in C57BL/...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
